Kyriakos Papadopoulos is an Oncology physician affiliated with South Texas Accelerated Research Therapeutics. OpenAlex indexes 760 publications with 18,307 citations (h-index 63); ClinicalTrials.gov lists 6 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Hematology / Oncology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4383 Medical Dr
San Antonio, TX 782293307
Telephone
210-593-5700Registry record last updated 11 Jul 2013.
Clinical trials
- A Study of OMP-336B11 in Subjects With Locally Advanced or Metastatic Tumors
Sponsor: OncoMed Pharmaceuticals, Inc.
- Study of PM060184 in Patients With Advanced Solid Tumors
Sponsor: PharmaMar
- Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors
Sponsor: TetraLogic Pharmaceuticals
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Celgene CorporationProgram year20252 payments
- Tempus AI, IncProgram year20242 payments
- Celgene CorporationProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
67.5%Histamine-1 Receptor Antagonist55.6%Diphenhydramine hcl100%Part B, office-administered≥20 patientsOpioid Agonist11.9%Hydrocodone-Acetaminophen100%Part D<11 patientsCancer & immunology
14.4%Cytochrome P450 17A1 Inhibitor7.5%Abiraterone Acetate100%Part D<11 patientsKinase inhibitor6.9%Brukinsa100%Part D<11 patientsMetabolism & gastrointestinal
10.6%Corticosteroid10.6%Prednisone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Amita Patnaik, MD
South Texas Accelerated Research Therapeutics
Drew Rasco, MD
South Texas Accelerated Research Therapeutics
Muralidhar Beeram, MD
South Texas Accelerated Research Therapeutics
Ronald Drengler, MD
South Texas Accelerated Research Therapeutics
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”